



AgiOS Research in Cancer Metabolism Highlighted at AACR Annual Meeting 2013

April 5, 2013

Cambridge, Mass. – April 5, 2013 – Agios Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that preclinical data from Agios' research in cancer metabolism will be highlighted in a major symposium at the American Association for Cancer Research (AACR) Annual Meeting 2013 taking place April 6-10, 2013 in Washington, DC.

"AACR brings together world leaders in cancer research, and cancer metabolism continues to be an area of increased focus and discussion at this event," said Scott Biller, Ph.D., chief scientific officer. "The Agios presentation focuses on our understanding of how targeted IDH inhibitors can have a profound impact on the differentiation of cancer cells. Our research underscores the importance of IDH as a drug target for developing potentially transformative treatment options for cancer patients."

The schedule for Agios' presentations is as follows:

Date & Time: Tuesday, April 9, 2013 from 11:55a.m.-12:15p.m. (EDT)

Session Title: Metabolic Vulnerabilities of Cancer Cells

Session Type: Major Symposium

Presentation Title: Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

Presenter: Katharine Yen, Ph.D., director, biology

Location: Ballroom C, Washington Convention Center

Date & Time: Tuesday, April 9, 2013 from 3:00-5:00p.m. (EDT)

Session Title: Metabolic Pathway Regulation in Cancer

Session Type: Minisymposium

Session Chairpersons: Katharine Yen, Ph.D., director, biology

Location: Room 150, Washington Convention Center

Dr. Yen's presentation focuses on mutations in the isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) genes, which are found in acute myeloid leukemia, brain cancer and several other tumor types. Dr. Yen will discuss the progress of Agios' IDH1 and IDH2 drug discovery programs and research into the role of IDH mutations in cancer.

About Agios Pharmaceuticals, Inc.

Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.